Browse by author
Lookup NU author(s): Dr Zakareya Gamie
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Introduction: Bone grafting is used to repair large bone defects and autograft is recognised as producing the best clinical outcome, which is partly due to its cellular component. When autograft is unavailable, allograft and bone graft substitutes can be used; however, they rely on the host bed to provide cellular osteogenic activity. Areas covered: Bone graft substitutes have the potential to benefit from the addition of stem cells aimed at enhancing the rate and quality of defect repair. Mesenchymal stem cells (MSCs) can be isolated from bone marrow or periosteum and culture expanded. Other sources of primary cells include muscle, adipose tissue, human umbilical cord and the pluripotent embryonic stem cells (ESCs). Expert opinion: MSCs isolated from bone marrow have been the best characterised approach for osteogenic differentiation. Their use with synthetic scaffolds such as hydroxyapatite and tricalcium phosphate has produced promising clinical results. MSCs derived from adipose tissue, muscle or human umbilical cord cells combined with various scaffolds are an attractive option. Further in vivo and clinical investigation of their potential is required. Pluripotent ESCs have a theoretical advantage over MSCs; however, purification, cell-specific differentiation, effective delivery vehicles-scaffolds and teratogenesis control are still under in vitro and in vivo evaluation.
Author(s): Gamie Z, Tran GT, Vyzas G, Korres N, Heliotis M, Mantalaris A, Tsiridis E
Publication type: Review
Publication status: Published
Journal: Expert Opinion on Biological Therapy
Year: 2012
Volume: 12
Issue: 6
Pages: 713-729
Print publication date: 01/06/2012
ISSN (print): 1471-2598
ISSN (electronic): 1744-7682
Publisher: INFORMA HEALTHCARE
URL: http://dx.doi.org/10.1517/14712598.2012.679652
DOI: 10.1517/14712598.2012.679652
